Immunocellular Therapeutics

Immunocellular Therapeutics Phase 3 ICT 107 Vaccine Clinical Trial for Glioblastoma Patients

ICT 107 is a vaccine for glioblastoma cancer stem cells.  This vaccine was developed by a company called ImmunoCellular Therapeutics, (https://www.imuc.com ) primarily by researchers at Cedars Sinai in Los Angeles.  https://virtualtrials.com/newsarticle.cfm?item=6107  This protocol has completed phase II testing and now it is open to a phase 3 randomized double blind control study for newly diagnosed glioblastoma.  […]

New High Throughput Screening Clinical Trial for Glioblastoma Brain Tumor Patients at Swedish, Seattle, WA

Swedish Medical Center in Seattle announces a clinical trial in humans for the treatment of glioblastoma, based on investigational high throughput screening of FDA-approved compounds targeting a patient’s own tumor stem cells. This trial will utilize a personalized approach for the treatment of tumor cells that have been screened against dozens of compounds, to find […]

Brain Tumors 101 Series: “MGMT Methylation in Glioblastoma Brain Tumors”

BrainCancer.org presents its 6th video in the Brain Tumors 101 series, “MGMT Methylation in Glioblastoma Brain Tumors”. This is Part 2 of 2 on MGMT Methylation. Topics discussed in this video include: Temozolomide and impact on MGMT Methylated and Unmethylated glioblastoma brain tumors, prognosis for unmethylated vs methylated brain tumors, and details on how to […]